Li Watsek
Stock Analyst at Cantor Fitzgerald
(1.23)
# 3,405
Out of 4,711 analysts
78
Total ratings
35.53%
Success rate
-16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $1.62 | - | 6 | Dec 18, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $25.61 | - | 1 | Dec 17, 2024 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $9.01 | - | 10 | Dec 9, 2024 | |
| AFMD Affimed | Reiterates: Overweight | n/a | $1.19 | - | 7 | Nov 19, 2024 | |
| ASND Ascendis Pharma | Reiterates: Overweight | $170 | $136.38 | +24.65% | 15 | Nov 15, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $15.50 | - | 4 | Oct 7, 2024 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $18.48 | - | 4 | Sep 9, 2024 | |
| YMAB Y-mAbs Therapeutics | Reiterates: Overweight | $20 | $8.28 | +141.55% | 2 | Sep 9, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Overweight | n/a | $14.68 | - | 5 | Sep 9, 2024 | |
| CRIS Curis | Reiterates: Overweight | n/a | $3.08 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.21 | - | 5 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.99 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $0.89 | +237.84% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $220 | $5.96 | +3,591.28% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.68 | +197.62% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 | $0.28 | +13,520.07% | 2 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $2.37 | +1,503.38% | 1 | Aug 12, 2022 |
ALX Oncology Holdings
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.62
Upside: -
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $25.61
Upside: -
Kura Oncology
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.01
Upside: -
Affimed
Nov 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.19
Upside: -
Ascendis Pharma
Nov 15, 2024
Reiterates: Overweight
Price Target: $170
Current: $136.38
Upside: +24.65%
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.50
Upside: -
Arvinas
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.48
Upside: -
Y-mAbs Therapeutics
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $8.28
Upside: +141.55%
Bicycle Therapeutics
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.68
Upside: -
Curis
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.08
Upside: -
Apr 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.21
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.99
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $0.89
Upside: +237.84%
Sep 7, 2023
Reiterates: Overweight
Price Target: $220
Current: $5.96
Upside: +3,591.28%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.68
Upside: +197.62%
Sep 7, 2023
Reiterates: Overweight
Price Target: $38
Current: $0.28
Upside: +13,520.07%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $2.37
Upside: +1,503.38%